Supernus Pharmaceuticals, a company focused on developing and commercializing products for the treatment of central nervous system diseases, will potentially add up to 160 new jobs over the next five years as part of its expansion in Montgomery County.
The company – currently located in Rockville – is relocating its headquarters, research and development, and pilot-scale manufacturing operations to an 118,000 square-foot space on Quince Orchard Road in Gaithersburg. Supernus, which currently employs 156 workers in the county, expects to move into the new space in 2019, with construction wrapping up in 2020.
“Supernus is excited to continue its long tenure in Montgomery County and to expand its headquarters in support of our company’s growth,” said Frank Mottola Vice President of Quality, GMP Operations and Information Technology of Supernus Pharmaceuticals.
For the past 25 years, Supernus Pharmaceuticals (first as a development organization, then as a U.S. subsidiary of Shire, and now as an independent company) has worked toward creating new medicines in neurology and psychiatry. The company currently markets Trokendi XR® to prevent migraines and treat epilepsy, as well as Oxtellar XR® for epilepsy, and is developing several product candidates for the psychiatry market, including potential treatments for impulsive aggression and attention-deficit/hyperactivity disorder (ADHD).
“Supernus is one of the fastest growing biotech/pharma companies in our region and we are proud to support their continued growth in Maryland," said Maryland Commerce Secretary Mike Gill.